CareLit · DOI-Nachweis · Pneumologie
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use*
DOI 10.1055/s-0039-3403188
Bibliografische Angaben
Nachweis in CareLit
Autor:innenR Wiewrodt, M Vonk, O Distler, D Furst, E Hachulla, S Johnson, S Assassi, L Meng, M Quaresma, M Alves, E Clerisme-Beaty, WA Wuyts
ZeitschriftPneumologie
AusgabeS 01 S 01/2020
Jahrgang / SeitenJg. 74
Kernaussage aus der Literatur
Abstract-Vorschau
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use*
Zitieren
Zitierempfehlung
R Wiewrodt, M Vonk, O Distler, D Furst, E Hachulla, S Johnson, S Assassi, L Meng, M Quaresma, M Alves, E Clerisme-Beaty, WA Wuyts (2020) Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use*. Pneumologie, 74 (S 01 S 01). https://doi.org/10.1055/s-0039-3403188
Mit CareLit weiterarbeiten